Described are methods of inhibiting neurodegeneration in a subject by administering to the subject an agent that prevents (alpha)-syn PFF from binding to its receptor. The agent may be a small molecule chemical compound, antibody, nucleic acid molecule, or polypeptide. Drug screening methods are also provided.
THERAPEUTIC USES OF LAG3 THE (alpha)-SYNUCLEIN TRANSMISSION RECEPTOR